Proteomics

Dataset Information

0

Phosphoproteomics of in vivo resistance to EGFR-targeted therapy in lung cancer cells


ABSTRACT: Mass spectrometry-based quantitative proteomics profiling of in vivo signaling changes in 41 therapy resistant (osimertinib or EGFR/Met bispecific antibody treament) tumors from four xenograft NSCLC models.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

SUBMITTER: Kristina Bennet Emdal  

LAB HEAD: Forest White

PROVIDER: PXD006114 | Pride | 2017-08-28

REPOSITORIES: Pride

altmetric image

Publications

Characterization of <i>In Vivo</i> Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.

Emdal Kristina B KB   Dittmann Antje A   Reddy Raven J RJ   Lescarbeau Rebecca S RS   Moores Sheri L SL   Laquerre Sylvie S   White Forest M FM  

Molecular cancer therapeutics 20170822 11


Approximately 10% of non-small cell lung cancer (NSCLC) patients in the United States and 40% of NSCLC patients in Asia have activating epidermal growth factor receptor (EGFR) mutations and are eligible to receive targeted anti-EGFR therapy. Despite an extension of life expectancy associated with this treatment, resistance to EGFR tyrosine kinase inhibitors and anti-EGFR antibodies is almost inevitable. To identify additional signaling routes that can be cotargeted to overcome resistance, we qua  ...[more]

Similar Datasets

| E-GEOD-38310 | biostudies-arrayexpress
| E-GEOD-31852 | biostudies-arrayexpress
2018-11-06 | PXD006769 | Pride
2014-06-01 | GSE31852 | GEO
2023-10-09 | PXD025361 | Pride
2012-05-30 | GSE38310 | GEO
2023-02-23 | GSE171920 | GEO
2024-03-24 | GSE261880 | GEO
2020-11-12 | GSE159547 | GEO
2015-03-07 | GSE66604 | GEO